SUNNYVALE, Calif. — January 22, 2026 — Leads & Copy —Intuitive (Nasdaq: ISRG) has released its financial results for the quarter ended December 31, 2025, showcasing significant growth in procedures, system placements, and revenue.
Worldwide procedures, combining da Vinci and Ion, increased by approximately 18% compared to the fourth quarter of 2024. Da Vinci procedures grew by about 17%, while Ion procedures saw a substantial increase of approximately 44%.
The company placed 532 da Vinci surgical systems, up from 493 in the same period of the previous year. This included 303 da Vinci 5 systems, compared to 174 in Q4 2024. Ion endoluminal system placements, however, decreased to 42 from 69 in the fourth quarter of 2024.
Intuitive’s da Vinci surgical system installed base reached 11,106 systems as of December 31, 2025, a 12% increase from 9,902 systems the year prior. The Ion endoluminal system installed base also grew to 995 systems, a 24% rise from 805 systems as of December 31, 2024.
Fourth quarter revenue reached $2.87 billion, a 19% increase compared to $2.41 billion in the fourth quarter of 2024.
GAAP net income attributable to Intuitive was $795 million, or $2.21 per diluted share, compared to $686 million, or $1.88 per diluted share, in the fourth quarter of 2024.
Non-GAAP net income attributable to Intuitive was $914 million, or $2.53 per diluted share, compared to $805 million, or $2.21 per diluted share, in the fourth quarter of 2024. The non-GAAP net income included tax benefits of $0.11 per diluted share related to the release of unrecognized tax benefits.
Expenses for the fourth quarter included a $70 million contribution to the Intuitive Foundation, compared to $45 million in the fourth quarter of 2024.
Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on both GAAP and non-GAAP bases. The non-GAAP measures are described and reconciled to GAAP measures at the end of the release.
Instruments and accessories revenue increased by 17% to $1.66 billion, driven by growth in da Vinci and Ion procedure volumes.
Systems revenue was $786 million, reflecting increased da Vinci system placements, a higher lease installed base, and higher average selling prices.
GAAP income from operations increased to $864 million, including share-based compensation expense of $207 million. Non-GAAP income from operations increased to $1.07 billion.
The company ended the quarter with $9.03 billion in cash, cash equivalents, and investments, an increase of $0.60 billion during the quarter.
Looking ahead to 2026, Intuitive expects da Vinci procedure growth of approximately 13% to 15%. Non-GAAP gross profit margin is projected to be between 67% and 68% of revenue, including an estimated tariff impact of 1.2%. Non-GAAP operating expense growth is expected to be between 11% and 15%.
These forward-looking statements are based on current expectations and are subject to risks and uncertainties, as detailed in the company’s filings with the Securities and Exchange Commission.
Intuitive held a teleconference at 1:30 p.m. PDT today to discuss these results. A webcast replay is available on the company’s website.
Intuitive, headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Their technologies include the da Vinci surgical systems and the Ion endoluminal system.
Contact: Investor Relations, (408) 523-2161
Source: Intuitive
